Johannesburg-based investment banker Cheri Nel is the driving force behind a court case that may result in dramatically expanded access to life-changing new cystic fibrosis (CF) medicines. Biénne Huisman asked Nel about the motivation behind the court case and what it is like to live with CF.
Spotlight recently reported on a court case aimed at expanding access to breakthrough new treatments for cystic fibrosis (CF) and on how this debilitating disease is diagnosed in South Africa. Now, in Part 3 of this special series on CF, Catherine Tomlinson turns the spotlight on how the disease is currently being treated in the country, while the new treatments are still largely out of reach.
Six months after Spotlight first reported on the plight of stoma patients experiencing shortages of colostomy and urostomy bags at Chris Hani Baragwanath Hospital in Gauteng, users are still reporting shortages at Baragwanath and other hospitals in the province. Thabo Molelekwa reports.
In recent weeks, cystic fibrosis (CF) has been in the headlines because of a court case about access to new treatments for the genetic condition. After having reported on the court case, Catherine Tomlinson now unpacks how CF is diagnosed in South Africa and why so many cases here fall through the cracks. The good news, she reports, is that efforts are underway to establish a national infant screening programme.
Cystic fibrosis (CF) is a debilitating and often deadly disease. Until recently, the only treatments for its symptoms were difficult to administer and time-consuming. Life-changing new treatments that dramatically improve the prognosis for people with the disease have been developed, but they are expensive and Vertex, the US company making the drugs, has decided against registering the drugs in South Africa. Cheri Nel, a woman living with CF, is now taking Vertex on in a South African court. Catherine Tomlinson unpacks the details.
Despite some improvement, the community-led monitoring group Ritshidze’s second report on key populations highlights that sex workers, people who use drugs and LGBTQIA+ community members are often still discriminated against when trying to access public health facilities. This can lead to treatment interruptions and some stopping their clinic visits. Nthusang Lefafa reports.
Lenalidomide is an important medicine used for the treatment of multiple myeloma – a type of bone marrow cancer that is not curable and typically requires long-term, ongoing treatment. Over the last decade, the price of this drug has fluctuated dramatically in South Africa and patients and their doctors have gone to extreme lengths to access it. Catherine Tomlinson unpacks the remarkable recent history of lenalidomide.
Our public health system is creating a new type of disability – ostomates who, with access to the necessary care and medical consumables could live long and fulfilled lives, but who every day are subjected to the indignities of inadequate care, writes colorectal cancer survivor and ostomate, Faizel Jacobs.
The South African Health Products Regulatory Authority has often made the headlines in recent years – be it in relation to COVID-19 vaccines, access to ivermectin, the approval of an HIV prevention injection, or most recently the clearing of inherited backlogs. Catherine Tomlinson assesses the state of South Africa’s medicines regulator as 2022 draws to a close.
Antibiotics play a vital role in the management of bacterial infections, reducing illness, and preventing many deaths. A 2011 report from the UK estimated that they have increased life expectancy by 20 years. However, the extensive use of antibiotics has resulted in drug resistance that threatens to reverse their life-saving power and if the situation is not reversed, it has been estimated that by 2050 as many as 10 million people will die annually of drug-resistant infections. Tiyese Jeranji looks at how antimicrobial resistance plays out in South Africa and the role of pharmacists in the fight against it.
South Africa is expected to begin piloting the every-other-month HIV prevention shot early next year, according to the international medicine financing initiative Unitaid. New modelling shows that the injection could prevent as many as 52 000 new HIV infections in the next two decades. But to be cost-effective in South Africa, the research argues, the price of the injection must fall to levels drugmaker ViiV Healthcare says are unrealistic. Laura Lopez Gonzalez reports.
Though South Africa has in some respects done well in the provision of sexual and reproductive health services for adolescent girls and young women, significant gaps remain. Tiyese Jeranji takes an in-depth look at the current policy landscape and asks how well the implementation of the policies measures up to their lofty ambitions.
